DRD1 and glioblastoma: Lastly, a dopamine receptor agonist, carmoxirole, was included due to its potential to modulate cAMP production, with dopamine receptor D1 inhibiting GBM tumorigenicity and dopamine receptor D2 modulating GBM survival and death [82,83].